Abstract
Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropathy (CIDP). Various scales have been proposed in recent years, some now commonly utilized in daily clinical practice. The available evidence base relies itself on randomized controlled trial data obtained over the past 30 years, with several studies using different primary and secondary outcomes. We here review the different outcome measures used in CIDP research in relation to those currently recommended for clinical management. We consider the evidence base for CIDP treatment from the primary and secondary outcomes used in these studies and attempt to assess how this may relate to current clinical practice of routine evaluation of treatment effects and long-term monitoring.
| Original language | English |
|---|---|
| Pages (from-to) | 259-266 |
| Number of pages | 8 |
| Journal | Neurodegenerative disease management |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 3 Oct 2019 |
Bibliographical note
For full bibliographic citation, please refer to the version available at www.futuremedicine.com; https://www.futuremedicine.com/doi/abs/10.2217/nmt-2019-0009?journalCode=nmtKeywords
- chronic inflammatory demyelinating polyneuropathy
- clinical practice
- outcome measures